Close Menu
Business Voice NowBusiness Voice Now
    Facebook X (Twitter) Instagram
    Business Voice NowBusiness Voice Now
    Subscribe
    • Markets
      • BFSI
      • Capital Goods
    • Business
      • FMCG
      • Retail
      • Quick Commerce
      • Startups
    • Healthcare
    • Technology
    • Energy
    • Voices
      • Entrepreneur – CXO Stories
      • Corporate Office story
    • E Magazine
      • Year 2026
        • August 2026
        • July 2026
    Business Voice NowBusiness Voice Now
    Home»Business»Chandan Healthcare Sharpens Focus on High-Margin Diagnostics Business Through Strategic Divestment
    Business

    Chandan Healthcare Sharpens Focus on High-Margin Diagnostics Business Through Strategic Divestment

    WebDeskBy WebDeskAugust 8, 2026No Comments3 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Email
    Follow Us
    Google News Flipboard Threads
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Lucknow (Uttar Pradesh) [India], August 8: Chandan Healthcare Limited (NSE – CHANDAN), one of the leading diagnostic and healthcare services providers, has announced the strategic divestment of its entire shareholding in Chandan Pharmacy Limited (“CPL”), reinforcing its focus on scaling its core, higher-margin diagnostics business.

    The divestment aligns with Chandan Healthcare’s strategy to sharpen its focus on the higher-margin diagnostics business. The transaction will simplify the business structure and enable greater management and capital allocation towards expanding the Company’s core diagnostics operations.

    Key Strategic Benefits

    • Improved Margin Profile: Deconsolidation of the lower-margin pharmacy business is expected to improve the overall business mix and enable the stronger profitability of diagnostics to reflect more clearly in the Company’s consolidated financial performance.
    • Sharper Focus on Core Diagnostics: Greater management bandwidth and resources can be directed towards expanding the diagnostics network, increasing capacity utilisation and scaling the Company’s core operations.
    • Capital Redeployment Towards Higher-Return Assets: Proceeds from the divestment are proposed to be deployed towards the development of new diagnostic centres and capacity expansion. This will enable the Company to reallocate capital from a lower-margin business towards higher-EBITDA opportunities.
    • Simplified Business Structure: A more focused diagnostics-led structure is expected to provide greater visibility into the scale, growth and profitability of the core business while enabling more relevant benchmarking with diagnostics-focused peers.

    Transaction Details

    The Board has approved the divestment of Chandan Healthcare’s entire 53.56% stake in Chandan Pharmacy Limited to Chandan Hospital Limited for a consideration of approximately ₹16.77 crore. The consideration is based on CPL’s independently determined total valuation of approximately ₹31.31 crore, following which CPL will cease to be a subsidiary of the Company.

    Building a Focused Diagnostics Platform

    Going forward, Chandan Healthcare intends to deploy greater financial and managerial resources towards expanding its diagnostics footprint, adding new centres, strengthening capacity and driving higher utilisation across its network.

    The strategic realignment is expected to result in a simpler and more focused business structure, with a stronger margin profile and future growth increasingly driven by the scale-up of the Company’s core diagnostics operations.

    About Chandan Healthcare Limited

    Chandan Healthcare Limited, established in 2003, is one of India’s leading providers of diagnostic and pharmacy services and a key entity of the Chandan Group. The Company delivers a comprehensive range of pathology and radiology services through its expanding network across India.

    As on June 30, 2026, the Company operates 327 diagnostic centres including 264 operational franchise centres, strengthening its presence across urban, semi-urban and emerging markets. Its diagnostic portfolio comprises more than 3,000 pathology tests and 500+ radiology tests, including blood tests, X-ray, ECG, Ultrasound, CT scan, MRI and several other specialized diagnostic investigations. The Company’s network includes NABL and NABH accredited pathology laboratories and radiology centres, reflecting its commitment to delivering reliable, high-quality diagnostic services.

    Chandan Healthcare operates through a diversified business model comprising B2C (Retail Customers), B2B (Institutional & Corporate Clients) and B2G (Government PPP Contracts), providing a balanced and scalable revenue profile while catering to a wide spectrum of healthcare needs.

    The Company was listed on the NSE Emerge platform on February 17, 2025. 

    During FY26, the Company reported Total Income of ₹280.67 Cr, EBITDA of ₹56.84 Cr and Profit After Tax (PAT) of ₹27.06 Cr, reflecting its continued operational growth and financial strength.

    If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.

    Business
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    WebDesk
    • Website

    Related Posts

    Hoora Crosses 1,200 Partner Manager Franchises, Targets 2,000 by End of 2026

    September 15, 2026

    Furlicks Goes from 6 to 22 SKUs: Fredun Pharmaceuticals Ltd. Accelerates Pet Wellness Expansion

    September 15, 2026

    Can Fin Homes Showcases ‘Project Tejas’, its Rs 296.95-Crore Enterprise Digital Transformation Programme

    September 15, 2026

    Comments are closed.

    Recent Post
    • Hoora Crosses 1,200 Partner Manager Franchises, Targets 2,000 by End of 2026
    • Why Experts Rate DigiTap the Best Crypto Presale: Live Fintech App Beats Pure Roadmap Speculation
    • Furlicks Goes from 6 to 22 SKUs: Fredun Pharmaceuticals Ltd. Accelerates Pet Wellness Expansion
    • NPC West India Championship and IPL Gujarat Championship to Be Held in Surat on November 22, 2026
    • Can Fin Homes Showcases ‘Project Tejas’, its Rs 296.95-Crore Enterprise Digital Transformation Programme
    • Valiance Solutions Launches Audit AI, a New Point Solution Built on Its Multimodal Platform, to Automate End-to-End Audit Verification
    • Mr. Rahul Jain Honoured with Accountancy Excellence Award – 2026
    • REHAU Opens Second House of REHAU in Bengaluru, Bringing Its Complete Interior Solutions Experience Under One Roof

    Type above and press Enter to search. Press Esc to cancel.